Replies to post #165 on Boston's research

[boston745]

Sintx just added 5 new directors to its board doubling its board members. The first one mentioned in the press release helped guide Sintx through going public. If there is going to be a Reverse Merger then he'll help guide it again through this transition.

Mr. Moyes served as CFO of Amedica from 2013 to 2014 and was a Board Member during the Company’s 2014 initial public offering and initial listing on the Nasdaq Capital Market.

This looks good for a potential Medtronic partnership in the future. I wonder if hes related to an early Sintx investor Allan Lyons and/or former Employee Dana Lyons who joined Sintx from Zimmer Biomet before divestment of its spine division/Amedica?

Chris Lyons brings more than 35 years of experience in the musculoskeletal and spine markets, with a strong focus on business development, M&A, and strategic growth. He spent 15 years at Smith & Nephew in senior commercial roles before joining Medtronic Spine and Biologics, where he led global business development for over a decade. At Medtronic, he managed acquisitions, investments, and partnerships worldwide.

They also added Honigblum (CSO) and Bob Mitchell to the boards. Both of these individuals seem connected to investments with Honigblum helping Sintx raise over 100m in financing when it was private and Mr Mitchell being an advisor for Dubai Health fund that specializes in investing in transformational healthcare companies which Sintx is. Looks like Sintx is about to undergo a major change. With Mr Mitchell on the board i suspect Sintx is going to get significant funding from TVM in the future. It'll need it to tap its over 300bn in markets

As a former board member and early financial backer, Mr. Honigblum helped raise over $100 million in private funding for the company across multiple rounds....
His background includes investment banking, founding and scaling of medtech companies and extensive experience in capital formation and business strategy.

advisor to TVM Capital Healthcare in Dubai. His expertise spans operational leadership, commercialization, and strategic investments.

https://finance.yahoo.com/news/sintx-technologies-announces-strategic-changes-120000123.html

========================================

Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn
Cancer Treatment (microspheres) = $5-$15bn

Total = $330bn-340bn

Sources:
https://web.archive.org/web/2024040...ogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/...y-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market